Known safety concerns, contraindications, and risk factors.
Active cancer or history of hormone-sensitive malignancy
GH and IGF-1 promote cellular proliferation. Any active or hormone-responsive cancer is an absolute contraindication.
Pregnancy, breastfeeding, or planning conception
Animal studies on ghrelin receptor agonists show negative effects on fertilisation, implantation, and embryo-fetal development. No human reproductive safety data exists.
Uncontrolled diabetes or metabolic syndrome
Ipamorelin alters glucose metabolism and insulin secretion. Poorly managed blood sugar is a contraindication. Concurrent use with insulin or oral hypoglycaemics requires dose adjustment.
Severe cardiovascular disease
Potential impacts on heart rate and fluid balance. Stable cardiac function required before use.
Concurrent use of specific medications
Insulin, diabetes medications, thyroid medications, and corticosteroids may interact with the somatotropic axis or glucose regulation. Diltiazem, yohimbine, propranolol, and atropine inhibit Ipamorelin-evoked insulin release.